NEWS
Microtox® BT Evaluation of SARS-CoV-2 From Breath Test with Clinical Samples
Average Virus Breath Condensate Digital Signal 9X Larger Than Control DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces [...]
Conference “Ecotoxicology In Covid 19 Times”
Deepverge Featured at Italian Government Conference Deepverge was honoured to be featured today at the Italian Government conference on Covid-19 [...]
Introducing Our New Name And Logo And The Rationale Behind It
Today, we want to introduce you to our new name and logo The Integumen name and brand has served us [...]
The Mission to Detect Covid in Real Time in Wastewater
By Fin Murray, COO of Integumen, MD of Rinocloud. Almost 5 years ago our team at Rinocloud, a subsidiary of [...]
Integumen Partners with Avacta PLC For Novel SARS-CoV-2 Sensors
Collaboration Offers Hotspot Detection Monitoring in Wastewater Integumen has signed a Material Transfer Agreement ("MTA") with Avacta plc ("Avacta") to [...]
Launch of ecowaterOS real-time water monitoring, recovery, treatment and recycling
Expansion of sales and science team Integumen announces the launch of ecowaterOS (“Ecological Water Operating System”), a [...]
First RAWTest commercial AI agreement for industrial wastewater utilities
Integumen’s subsidiary Rinocloud today announces that it has entered into a commercial and AI development partnership with Acumen Software (Pty) [...]
Integumen Signs Cooperative Alliance MOU With Innocare Group, Shanghai, China
Trading update: Unaudited Revenues up 366% to £1m Integumen’s subsidiary Labskin today announces that it has signed a Memorandum of [...]
Interim Report 2019
Continued strong growth towards profitability Integumen (LSE: SKIN), the vertically integrated skin product test services company, today announces its interim [...]
How AI is Revolutionising Healthcare and Skin Disease
We have entered a new era where an Artificially Intelligent (AI) Laboratory today is becoming more science, than science fiction. [...]
Cloning The Skin Microbiome On Labskin
Labskin breakthrough clones 16 human skin swabs into 54 living microbiome test subjects Labskin scientists cloned 16 swabs of skin [...]
Wound pHase CBD Infused Chronic Woundcare and Burns Products
Integumen today announces the expansion of its wound care division, LifeScienceHub Ltd (Wound pHase), as it extends its license technology [...]
Trading Update H1 2019
Strong H1 2019 Revenue Growth Continues Trading Update The positive results of major restructuring in H2 2018 has delivered accelerated [...]
Final Results 2018
Integumen (LSE: SKIN), today announces its final results for the year ended 31 December 2018. Highlights Total revenue £501k (including discontinued [...]
3 Labskin contracts with CBD
Integumen today announces that Labskin AI, the virtual laboratory platform, has entered into testing agreements with three new clients – [...]
Trading Update & Board Changes May 2019
Trading update – board changes Trading Update Integumen announces the resignation of Tony Richardson as Chairman and a director of [...]
Labskin Clones Human Skin Environment for Clinical Trials
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials Integumen today announces the roll-out of [...]
Appointment of Fionán Murray, as Group Sales Director
Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on [...]
Integumen Investor Event
Turner Pope Investor Evening Integumen is pleased to announce that Gerry Brandon, the Company’s CEO, will be presenting at an [...]
STOER For Men Rehydrates Skin in 24 Hours
Integumen today announces the completion of development and launch of a new dandruff test on its animal-free Labskin test platform. [...]
Acquisition of Rinocloud Transforms Labskin AI Platform
Proposed Placing and Subscription of £2.518m Acquisition, Placing & Subscription Integumen plc, (AIM: SKIN, is pleased to announce that the [...]
Labskin Deferred Loan Digital Automation Equipment Deal
Labskin secures digital automation and integration through £400,000 Cellulac – Integumen deferred loan agreement Integumen plc (AIM: SKIN), is pleased [...]
STOER For Men With CBD oil
Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin Integumen plc (AIM: SKIN) is pleased [...]
Trading Update January 2019
Restructuring is Accelerating Growth into 2019 Trading Update The Company is pleased to announce the positive results of major restructuring [...]
TSpro Disposal Removes £1.19m Liabilities
Divestment of TSPro GmbH to remove c€1.34m (£1.19m) of short and long term liabilities from Integumen Today the Company announces [...]